company background image
IMUX

Immunic NasdaqGS:IMUX Stock Report

Last Price

US$1.67

Market Cap

US$74.2m

7D

-0.6%

1Y

-85.2%

Updated

20 Mar, 2023

Data

Company Financials +

IMUX Stock Overview

About the company

Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and other chronic inflammatory and autoimmune diseases, as well as to treat coronavirus disease. The company is also developing IMU-935, an inverse agonist of ROR?t; and IMU-856 for the restoration of the intestinal barrier function in patients suffering from diseases, such as inflammatory bowel disease, irritable bowel syndrome with diarrhea, immune checkpoint inhibitor induced colitis, and other intestinal barrier function diseases. Immunic, Inc. is headquartered in New York, New York.

Snowflake Analysis

IMUX fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

Capture your thoughts, links and company narrative

Immunic, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Immunic
Historical stock prices
Current Share PriceUS$1.67
52 Week HighUS$12.64
52 Week LowUS$1.11
Beta1.7
1 Month Change-16.92%
3 Month Change41.53%
1 Year Change-85.16%
3 Year Change-68.25%
5 Year Changen/a
Change since IPO-93.08%

Recent News & Updates

Recent updates

Immunic sinks ~74% after hours as phase 1b psoriasis trial fails to separate from placebo

Oct 20

Immunic stock gains on $60M oversubscribed PIPE financing

Oct 10

Immunic GAAP EPS of -$0.72 in-line

Aug 04

Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely

Jul 27
Here's Why Immunic (NASDAQ:IMUX) Must Use Its Cash Wisely

Is Immunic (NASDAQ:IMUX) In A Good Position To Invest In Growth?

Apr 13
Is Immunic (NASDAQ:IMUX) In A Good Position To Invest In Growth?

Is Immunic (NASDAQ:IMUX) In A Good Position To Invest In Growth?

Dec 24
Is Immunic (NASDAQ:IMUX) In A Good Position To Invest In Growth?

Here's Why We're Watching Immunic's (NASDAQ:IMUX) Cash Burn Situation

Aug 13
Here's Why We're Watching Immunic's (NASDAQ:IMUX) Cash Burn Situation

We're Hopeful That Immunic (NASDAQ:IMUX) Will Use Its Cash Wisely

May 10
We're Hopeful That Immunic (NASDAQ:IMUX) Will Use Its Cash Wisely

Immunic EPS misses by $0.95

May 06

Immunic EPS misses by $0.07

Nov 05

Enrollment underway in Immunic's Phase 2 part of IMU-838 study in COVID-19

Nov 02

Immunic (IMUX) Investor Presentation - Slideshow

Oct 31

Shareholder Returns

IMUXUS BiotechsUS Market
7D-0.6%1.0%2.1%
1Y-85.2%-1.2%-12.8%

Return vs Industry: IMUX underperformed the US Biotechs industry which returned -3.3% over the past year.

Return vs Market: IMUX underperformed the US Market which returned -13.7% over the past year.

Price Volatility

Is IMUX's price volatile compared to industry and market?
IMUX volatility
IMUX Average Weekly Movement14.4%
Biotechs Industry Average Movement10.9%
Market Average Movement6.4%
10% most volatile stocks in US Market16.5%
10% least volatile stocks in US Market2.9%

Stable Share Price: IMUX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 14% a week.

Volatility Over Time: IMUX's weekly volatility has decreased from 21% to 14% over the past year, but is still higher than 75% of US stocks.

Immunic, Inc. Fundamentals Summary

How do Immunic's earnings and revenue compare to its market cap?
IMUX fundamental statistics
Market CapUS$74.15m
Earnings (TTM)-US$120.41m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
IMUX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$120.41m
Earnings-US$120.41m

Last Reported Earnings

Dec 31, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.71
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did IMUX perform over the long term?

See historical performance and comparison